Novo Holdings and EIFO invest €48 million in HealthCap IX to strengthen Nordic life sciences ecosystem
- Editor
- Apr 24
- 2 min read
Whats Happening:
Novo Holdings and the Export and Investment Fund of Denmark (EIFO) have jointly invested €48 million in HealthCap IX, a Swedish life sciences venture fund. This investment aims to strengthen the Nordic life sciences ecosystem by supporting early-stage companies emerging from academic and corporate research environments. HealthCap will establish a local presence in Copenhagen at the BioInnovation Institute to increase its focus on Nordic investment opportunities.
Key Moves:
Novo Holdings and EIFO invest €48 million in HealthCap IX
HealthCap to establish local presence in Copenhagen at BioInnovation Institute
Focus on supporting early-stage companies from academic and corporate research environments
By The Numbers:
HealthCap has invested in more than 130 companies
Developed over 30 approved pharmaceutical products
Created more than 50 innovative medical technologies
Key Quotes:
"We are proud to welcome two of Denmark's most respected investors as LPs in HealthCap IX." - Mårten Steen, Managing Partner, HealthCap
"We aim to support high-quality scientific projects in the Nordics and ensure they have the support needed to develop into well-structured companies with clinical and commercial success." - Daniel Rasmussen, Principal, Seed Investments, Novo Holdings
"HealthCap is a key player and a local anchor for Danish life sciences. It has the ability to attract international investment and collaboration, which is vital to securing sufficient funding for the region." - Rikke Michaela Greve, Investment Manager, EIFO
Bottom Line:
The €48 million investment by Novo Holdings and EIFO in HealthCap IX demonstrates a strong commitment to fostering innovation and growth in the Nordic life sciences sector. This collaboration aims to support early-stage companies, bridge the gap between academic research and commercial success, and strengthen the region's position as a global leader in life science innovation and entrepreneurship.
Comments